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Two distinct signaling pathways upregulate NMDA receptor
responses via two distinct metabotropic glutamate receptor
subtypes
Abstract
Molecular processes regulating the gain of NMDA receptors modulate diverse physiological and
pathological responses in the CNS. Group I metabotropic glutamate receptors (mGluRs), which
neighbor NMDA receptors and which can be coactivated by synaptically released glutamate, couple to
several different second messenger pathways, each of which could target NMDA receptors. In CA3
pyramidal cells we show that the activation of mGluR1 potentiates NMDA current via a
G-protein-independent mechanism involving Src kinase activation. In contrast, mGluR5-mediated
enhancement of NMDA current requires G-protein activation, triggering a signaling cascade including
protein kinase C and Src. These results indicate that one neurotransmitter, glutamate, can activate two
distinct and independent signaling systems to target the same effector. These two pathways are likely to
contribute significantly to the highly differentiated control of NMDA receptor function.
Two Distinct Signaling Pathways Upregulate NMDA Receptor
Responses via Two Distinct Metabotropic Glutamate
Receptor Subtypes
Pascal Benquet, Christine E. Gee, and Urs Gerber
Brain Research Institute, University of Zurich, CH-8057 Zurich, Switzerland
Molecular processes regulating the gain of NMDA receptors
modulate diverse physiological and pathological responses in
the CNS. Group I metabotropic glutamate receptors (mGluRs),
which neighbor NMDA receptors and which can be coactivated
by synaptically released glutamate, couple to several different
second messenger pathways, each of which could target
NMDA receptors. In CA3 pyramidal cells we show that the
activation of mGluR1 potentiates NMDA current via a
G-protein-independent mechanism involving Src kinase activa-
tion. In contrast, mGluR5-mediated enhancement of NMDA
current requires G-protein activation, triggering a signaling cas-
cade including protein kinase C and Src. These results indicate
that one neurotransmitter, glutamate, can activate two distinct
and independent signaling systems to target the same effector.
These two pathways are likely to contribute significantly to the
highly differentiated control of NMDA receptor function.
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Glutamatergic signaling via NMDA receptors is essential for
CNS function, controlling a wide range of responses from neu-
ronal development to synaptic plasticity. Accordingly, sensitive
mechanisms are in place to fine-tune NMDA responses, allowing
for the adaptation of gain to ambient requirements. An immedi-
ate form of NMDA receptor modulation is mediated by postsyn-
aptic metabotropic glutamate receptors (mGluRs), which fre-
quently neighbor NMDA receptors (Baude et al., 1993; Lujan et
al., 1996, 1997). Although interactions between mGluRs and
NMDA receptors first were described a decade ago, past studies
reached conflicting conclusions as to whether the stimulation of
mGluRs potentiates NMDA receptor activity (Aniksztejn et al.,
1991; Bleakman et al., 1992; Harvey and Collingridge, 1993) (for
review, see Anwyl, 1999; Valenti et al., 2002) or inhibits NMDA
responses (Yu et al., 1997; Wang et al., 1998; Zhong et al., 2000;
Snyder et al., 2001). There is, however, general agreement that
the postsynaptic mGluRs involved in NMDA response modula-
tion belong to Group I, either mGluR1 (Lan et al., 2001; Skeb-
erdis et al., 2001; Heidinger et al., 2002) or mGluR5 (Doherty et
al., 1997, 2000; Jia et al., 1998; Awad et al., 2000; Mannaioni et al.,
2001; Pisani et al., 2001).
A further unresolved issue is the mechanism underlying the
modulation of NMDA receptors by mGluRs. Group I mGluRs
are coupled positively via G-proteins to phospholipase C (PLC),
leading to the formation of diacylglycerol (DAG) and protein
kinase C (PKC) activation and to the production of inositol
trisphosphate (IP3), resulting in the release of Ca
2 from intra-
cellular stores (Conn and Pin, 1997). In addition, mGluRs can
signal via direct membrane-delimited pathways whereby
G-protein subunits may modulate ion channels directly (Swartz
and Bean, 1992; Trombley and Westbrook, 1992; McCool et al.,
1996; Yu et al., 1997) and via G-protein-independent transduc-
tion, resulting in Src tyrosine kinase activation (Heuss et al.,
1999). This diversity of second messenger systems, all of which
may target NMDA receptors, is suggestive of a complex intracel-
lular network capable of subtle regulation of NMDA receptor
function. Several earlier studies presented evidence for a PKC-
dependent pathway in the potentiation of NMDA responses by
mGluRs (Aniksztejn et al., 1991; Kelso et al., 1992; Pisani et al.,
1997; Ugolini et al., 1997; Skeberdis et al., 2001), but other
investigators reported a PKC-independent process (Harvey and
Collingridge, 1993; Kinney and Slater, 1993; Rahman and Neu-
man, 1996; Holohean et al., 1999). An established mechanism
underlying NMDA receptor upregulation involves tyrosine phos-
phorylation of the receptor via Src kinase (Salter, 1998), and a
signaling cascade involving PLC, PKC, and Src has been shown to
target NMDA receptors (Lu et al., 1999; Huang et al., 2001). It is
not known, however, whether the activation of mGluRs can
initiate this pathway.
Here we systematically assessed the role of the major transduc-
tion pathways coupled to Group I mGluRs in regulating NMDA
receptors. Experiments were performed in hippocampal CA3
pyramidal cells, which express both subtypes of Group I metabo-
tropic receptors, permitting us to evaluate the effects of selective
activation of either mGluR1 or mGluR5 in the same system.
MATERIALS AND METHODS
Slice culture preparation and electrophysiology. Hippocampal slice cultures
were prepared from 6-d-old Wistar rats as described previously (Ga¨h-
wiler et al., 1998) and maintained by using the roller-tube technique.
After 2–3 weeks in vitro the slice cultures were transferred to a recording
chamber with a volume of 1 ml on an upright microscope (Axioscope FS;
Zeiss, Oberkochen, Germany). Slices were superfused continuously at a
rate of 1–2 ml/min with saline containing (in mM) 137 NaCl, 2.7 KCl,
11.6 NaHCO3, 0.36 NaH2PO4, 0.48 MgCl2, 1.8 CaCl2, and 5.6 D-glucose
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plus 0.5 M tetrodotoxin (TTX) and 10 mg/ l phenol red pH-adjusted to
7.4, with an osmolarity of 310 mOsm and a bath temperature of 29°C.
Whole-cell voltage-clamp recordings were obtained from CA3 pyramidal
neurons held at 50 mV with an Axopatch 200A amplifier (Axon
Instruments, Foster City, CA). Recording pipettes (2–5 M) were filled
with (in mM) 130 K-gluconate, 10 NaCl, 1 MgCl2, 10 HEPES, 10 EGTA,
and 4 Mg-ATP (pH-adjusted to 7.3 with KOH; osmolarity 300 mOsm).
In the indicated experiments 10 mM EGTA was replaced with 10 mM
BAPTA. Series resistance (6–13 M) and input resistance were moni-
tored regularly. Currents were filtered at 2 kHz and analyzed off-line
(pClamp 7; Axon Instruments).
Induction of NMDA currents. NMDA currents were isolated pharma-
cologically by adding the AMPA/kainate antagonist 1,2,3,4-tetrahydro-
6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX; 40 M)
and the GABAA receptor antagonist picrotoxin (100 M). NMDA cur-
rent amplitudes were measured from baseline holding current to peak.
The maximum percentage of potentiation is the average value of at least
two NMDA current traces obtained during the peak effect of the agonists
and normalized with respect to the average NMDA current measured in
the three to five traces immediately preceding the application of agonists
(referred to as “baseline”). I–V curves of the NMDA response were
determined with a ramp protocol from70 to 0 mV (2 sec duration). The
ramp protocol was run before and during NMDA pressure application,
and the respective traces were subtracted to obtain the I–V curve of the
NMDA response in control. Then the same procedure was repeated after
the application of DHPG.
To determine whether potentiation of NMDA current by drug treat-
ment was significant, we used the paired Student’s t test on raw data.
When the effects of two treatments were compared on different neurons,
the unpaired Student’s t test was used. For multiple comparisons the
percentage of potentiation for each condition was compared by using the
one-way ANOVA, followed by Tukey’s test. A value of p  0.05 (*) was
considered statistically significant and also p  0.01 (**). All numerical
data are expressed as the means  SEM.
Drugs. (S)-3,5-dihydroxyphenylglycine (DHPG), (1S,3R)-1-aminocyclo-
pentane-trans-1,3-dicarboxylic acid (ACPD), (RS)-2-chloro-5-hydroxy-
phenylglycine (CHPG), 7-(hydroxyimino)cyclopropachromen-1a-carboxy-
lateethyl ester (CPCCOEt), (S)-()--amino-4-carboxy-2-methylbenzene-
acetic acid (LY367385), 2-methyl-6-(phenylethynyl)pyridine (MPEP),
and 2-[1-(3-dimethylaminopropyl) indol-3-yl]-3-(indol-3-yl) maleimide
(GF109203X) were purchased from Tocris Cookson (Bristol, UK).
Guanosine 5-O-(2-thiodiphosphate) trilithium salt (GDPS), NMDA,
picrotox in, 4 ,5,7-tr ihydrox y i soflavone (geni stein), and 4 ,7-
dihydroxyisoflavone (daidzein) were purchased from Sigma (St. Louis,
MO). Phorbol 12-myristate 13-acetate (PM A), 1-(6-[([17]-3-
methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl)-1 H-pyrrole-2,5-dione
(U-73122), and 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-
d]pyrimidine 1 (PP1) were purchased from Alexis (San Diego, CA).
NBQX was obtained from AG Scientific (San Diego, CA) and TTX
from Latoxan (Valence, France). 3-(( R)-2-carboxypiperazin-4yl)-
propyl-1-phosphonic acid (CPP) and baclofen were kindly provided by
Novartis (Basel, Switzerland). Stock solutions of DHPG, ACPD,
GDPS, NMDA, TTX, and CPP were prepared by dissolving in water
(for DHPG and GDPS freshly prepared every 14 and 3 d, respective-
ly). Stock solutions of CPCCOEt, MPEP, GF109203X, picrotoxin,
baclofen, genistein, daidzein, PMA, U-73122, and PP1 were prepared
in DMSO. The final concentrations of DMSO used during experiments
never exceeded 0.02%, which did not affect NMDA current potentia-
tion (n  7; see also experiments with daidzein). LY367385 stocks
were dissolved in 1.1 equivalent NaOH but were diluted 1000	 in
experiments, resulting in no measurable change in pH.
RESULTS
Activation of group I mGluRs potentiates
NMDA current
As observed previously in numerous brain regions, we found that
in CA3 pyramidal cells NMDA receptor-mediated currents were
enhanced by the concomitant activation of mGluRs (Fig. 1).
NMDA currents were induced repetitively in voltage-clamped
CA3 pyramidal cells (50 mV) by applying brief pressure pulses
(100–300 msec) to a micropipette filled with NMDA (100 M) at
40 sec intervals. NMDA responses were blocked completely by
the specific antagonist CPP (40 M; n  10; p  0.001). Position-
ing the puffer pipette at a distance of100 m from the recorded
cell in the absence of a pressure pulse did not alter the holding
current. The presence of TTX, NBQX, and picrotoxin in the bath
solution prevented the contamination of NMDA currents with
synaptic responses. Under these conditions, brief reversible
NMDA currents exhibiting minimal variations in amplitude could
be induced routinely for 1–2 hr. After a steady baseline of NMDA
responses was recorded, the application of the broad-spectrum
mGluR agonist ACPD (50 M for 4 min) or the group I agonist
DHPG (10 M for 2 min) increased the peak amplitude of
NMDA currents by 22  4% (n  6; p  0.05 vs baseline) and
38  5% (n  23; p  0.001 vs baseline), respectively. This effect
peaked rapidly, within 2 min, but reversal after washout of
metabotropic agonists was relatively slow (Fig. 1C). Apart from
the potentiation of NMDA current, DHPG (10 M for 2 min) or
ACPD (50 M for 4 min) induced an inward current associated
with an increase in input resistance (15  4%, n  19, p  0.01
for DHPG; 13  4%, n  7, p  0.05 for ACPD), as character-
ized previously (Gue´rineau et al., 1994). Repeated application of
mGluR agonists to the same preparation induced reproducible
responses. The potentiation of NMDA current induced by a
second application of DHPG (10 M for 2 min) or ACPD (50 M
Figure 1. Activation of group I mGluRs potentiates currents mediated
by NMDA receptors in CA3 pyramidal cells. A, NMDA currents induced
by the pressure application of NMDA (100 M for 200 msec) every 40 sec
(black arrows) are potentiated by the bath application of the specific group
I mGluR agonist DHPG (10 M for 2 min). The effect is transient and
reversible. B, Single NMDA current traces from the recording in A shown
at an expanded time scale before (1) during (2), and after (3) the washout
of DHPG. C, Average time course of the DHPG-induced potentiation
(n  23). D, Average current–voltage relationship of NMDA responses
obtained with a ramp protocol before ( filled circles) and after (open
circles) DHPG application (n 5; mean SEM of current is shown every
2 mV). Inset shows subtraction of control I–V plot from I–V plot after the
application of DHPG.
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for 4 min) corresponded to 93  6% (n  4; p 
 0.05) and 92 
16% (n  5; p 
 0.05), respectively, of the previous potentiation.
The extent of potentiation of the peak NMDA-evoked currents
was independent of membrane potential over the range from70
to 10 mV (Fig. 1D).
Potentiation of NMDA current by mGluRs involves
tyrosine kinase activation
The application of Src to CA3 pyramidal cells increases NMDA
currents (Xiong et al., 1999). Moreover, the activation of mGluRs
can lead to Src activation (Fiore et al., 1993; Siciliano et al., 1994;
Heuss et al., 1999; Boxall, 2000; Peavy et al., 2001). We therefore
tested whether the mGluR-dependent potentiation of NMDA
current requires tyrosine kinase activation. We found that the
DHPG-induced potentiation of NMDA current (41 6%, n 5;
p  0.05 vs baseline) was reduced substantially after the applica-
tion of the broad-spectrum tyrosine kinase antagonist genistein
(30 M for 15 min; 8  8%; p 
 0.05 vs baseline and p  0.01 vs
DHPG alone) (Fig. 2A2). The potentiation of NMDA current
was insensitive to the inactive genistein analog daidzein (30 M
for 15 min; 37 14%, n 5; p 0.05 vs baseline) (Fig. 2A3). The
application of PP1 (25 M for 15 min), a specific inhibitor of Src
kinase, also reduced the DHPG-induced potentiation of NMDA
current (58  12% before PP1 treatment, p  0.05 vs baseline
compared with 11  6% after PP1 treatment; n  5; p 
 0.05 vs
baseline and p  0.01 vs DHPG alone) (Fig. 2B). No effect on
NMDA currents was observed when genistein or PP1 was applied
alone, suggesting weak background phosphorylation of NMDA
receptors in CA3 cells in our preparation.
mGluR1 and mGluR5 mediate NMDA
current potentiation
In CA1 pyramidal cells and subthalamic neurons the enhance-
ment of NMDA current by mGluRs is mediated by mGluR5,
whereas mGluR1 activation is without effect (Awad et al., 2000;
Mannaioni et al., 2001). We found a similar mGluR5-mediated
potentiation of NMDA current in CA3 pyramidal cells. mGluR5
was stimulated either by applying the specific agonist CHPG (500
M for 2 min; n  8) (Fig. 3A) or by applying the group I agonist
DHPG (10 M for 2 min) in the presence of a saturating concen-
tration of the mGluR1 antagonist CPCCOEt (50 M for 10 min;
n  6) (Fig. 3B). Either approach resulted in a significant poten-
tiation in the amplitude of NMDA current (20 5%, p 0.05 for
CHPG vs baseline; 19 5%, p 0.05 for DHPG plus CPCCOEt
vs baseline). However, selective activation of mGluR5 resulted in
significantly less potentiation than that observed with the coacti-
vation of mGluR1 and mGluR5 with DHPG (DHPG plus CPC-
COEt vs DHPG alone; n  5; p  0.05) (Fig. 3D). We therefore
tested whether the selective activation of mGluR1 also increases
NMDA currents. When DHPG (10 M for 2 min) was applied to
cells in the presence of a saturating concentration of the mGluR5
antagonist MPEP (10 M for 10 min; n  5) (Fig. 3C), NMDA
current was potentiated significantly (18  4%; p  0.05 vs
baseline). Again, selective activation of mGluR1 induced less
potentiation than the coactivation of mGluR1 and mGluR5
(DHPG plus MPEP vs DHPG; n  5; p  0.01). Thus both
mGluR1 and mGluR5 mediate NMDA current potentiation in
CA3 pyramidal cells (Fig. 3D). No significant potentiation was
detected in the presence of both the mGluR1 and the mGluR5
antagonist (DHPG plus MPEP plus CPCCOEt, 9  4%; n  5;
p 
 0.05) (Fig. 3D).
G-protein blockade does not prevent mGluR-mediated
potentiation of NMDA current
Stimulation of mGluRs can activate Src via a G-protein-
independent signaling pathway in CA3 pyramidal cells (Heuss et
al., 1999). To determine whether this mechanism contributes to
the potentiation of NMDA currents, we examined the response to
mGluR activation in cells in which G-protein activity was blocked
by intracellular perfusion of GDPS (1 mM). To establish effec-
tive inhibition of G-protein function by GDPS, we waited until
the postsynaptic response to the bath-applied GABAB agonist
baclofen (20 M for 1 min) was blocked fully in each cell before
testing the effects of mGluR activation (124  30 pA just after
beginning whole-cell recording vs 5  5 pA after 20–40 min of
Figure 2. Src is required for mGluR-mediated potentiation of NMDA
current. A, Genistein, a broad-spectrum blocker of tyrosine kinase, in-
hibits DHPG-induced potentiation of NMDA current. A1, Single traces
from the same neuron show that the increase in NMDA current ampli-
tude induced by DHPG (10 M) is prevented in the presence of genistein
(30 M for 15 min). Genistein alone does not alter NMDA current. A2,
Averaged results from five cells comparing the effect on NMDA current
of 10 M DHPG alone (open circles) and in the presence of genistein
( filled circles). A3, Potentiation of NMDA current by 10 M DHPG is
inhibited by genistein (30 M; n  5) but not by its inactive analog
daidzein (30 M; n  5); *p  0.05. B, PP1, a specific inhibitor of Src
kinase, inhibits the DHPG-induced potentiation of NMDA current. B1,
Time course of action on peak NMDA current of DHPG (10 M for 2
min) before and after a 15 min application of 25 M PP1 in a represen-
tative cell. PP1 alone does not alter NMDA current. B2, Single NMDA
current traces from this cell. B3, Averaged results from five cells compar-
ing the effect on NMDA current of DHPG before (open circles) and after
( filled circles) PP1 incubation. B4, Pooled data comparing responses to
DHPG alone and DHPG in the presence of PP1 (n  5); *p  0.05.
Dotted lines indicate baseline or control responses.
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GDPS diffusion; n  6; p  0.001) (Fig. 4A). In addition,
GDPS prevented the increase in input resistance induced by
DHPG (1  2%, n  6 vs 15  4% in control, n  19; p  0.05;
data not shown), further indicating that the class of G-protein
associated with group I mGluRs was blocked effectively. Under
conditions of G-protein blockade, DHPG (10 M for 2 min) still
potentiated NMDA current (29  5%, n  6; p  0.01 vs
baseline) (Fig. 4B). Moreover, this G-protein-independent in-
crease in NMDA current was blocked by the Src inhibitor PP1 (25
M for 20 min; 1  4%, n  5; p 
 0.05 vs baseline) (Fig. 4F).
mGluR1, but not mGluR5, can potentiate NMDA
current via a G-protein-independent mechanism
To assess whether both group I mGluRs can signal via G-protein-
independent mechanisms, we repeated the above experiments but
selectively stimulated either mGluR1 or mGluR5. In GDPS-
treated cells in which baclofen no longer induced a response, the
application of the mGluR5-specific agonist CHPG (500 M for 2
Figure 3. Activation of either mGluR5 or mGluR1 potentiates NMDA
current. A, Average time course of NMDA current potentiation induced
by the mGluR5-specific agonist CHPG (500 M for 2 min; n  8).
Representative traces from one cell are shown (right). B, Alternatively,
mGluR5 was stimulated selectively by the application of DHPG (10 M
for 2 min) in the presence of a saturating concentration of the mGluR1
antagonist CPCCOEt (50 M for 10 min; n  6). Average time course
(lef t) and representative traces (right) are shown. C, mGluR1 was stimu-
lated selectively by the application of DHPG (10 M for 2 min) in the
presence of a saturating concentration of the mGluR5 antagonist MPEP
(10 M for 10 min). Average time course (lef t) and representative traces
(right) are shown. D, Pooled data indicate that, although the selective
activation of either mGluR5 (CHPG, n  8; CPCCOEt plus DHPG, n 
4) or mGluR1 (MPEP plus DHPG, n  5) significantly potentiates
NMDA current, greater potentiation is observed with the coactivation of
mGluR1 and mGluR5 (DHPG, n  23). No significant potentiation is
detected in the presence of both mGluR1 and mGluR5 antagonists
(CPCCOEt plus MPEP plus DHPG, n  5); *p  0.05 and **p  0.01.
Figure 4. G-protein-independent potentiation of NMDA current is me-
diated by mGluR1 but not by mGluR5. A, Within 3 min of establishing the
whole-cell configuration with a patch pipette containing 1 mM GDPS,
the application of baclofen (20 M for 1 min) induces an outward K
current. Having allowed 20–40 min for GDPS to diffuse into the cell,
reapplication of baclofen no longer produces a response, indicating a
blockade of the G-protein function (n  6). B, After the baclofen
response is blocked completely, DHPG (10 M for 2 min) still potentiates
NMDA current (n 6). Representative traces from one cell are shown on
the right. C, Average time course of NMDA current in six GDPS-treated
cells exposed to the mGluR5-specific agonist CHPG (500 M for 2 min),
indicating a lack of potentiation. Representative traces from one cell are
shown on the right. D, Average time course of NMDA current in five
GDPS-treated cells in which mGluR5 activation is obtained by applying
DHPG (10 M for 2 min) in the presence of a saturating concentration of
the mGluR1 antagonist LY367385 (50 M for 10 min), again showing that
NMDA current is not potentiated. Representative traces from one cell
are shown on the right. E, Average time course of NMDA current in five
GDPS-treated cells in which mGluR1 is activated selectively by applying
DHPG (10 M for 2 min) in the presence of a saturating concentration of
the mGluR5 antagonist MPEP (10 M for 10 min), showing marked
potentiation. Representative traces from one cell are shown on the right.
F, Pooled data for GDPS-treated cells showing that the activation of
mGluR1 plus mGluR5 with DHPG (n  6) significantly potentiates
NMDA current. Selective activation of mGluR5 with CHPG (n  6) or
LY367385 plus DHPG (n  5) does not potentiate NMDA current,
whereas the selective activation of mGluR1 (MPEP plus DHPG, n  5)
potentiates NMDA current to a similar degree, as does the coactivation of
mGluR1 plus mGluR5 with DHPG. DHPG-induced potentiation is
blocked completely by the Src inhibitor PP1 (25 M for 20 min; n  5);
**p  0.01.
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min) failed to potentiate NMDA current (3 5%, n 6; p
 0.05
vs baseline) (Fig. 4C). The same lack of effect was observed when
mGluR5 was stimulated by applying DHPG (10 M for 2 min) in
the presence of a saturating concentration of the mGluR1 antag-
onist LY367385 (50 M for 10 min) (5  6%, n  5; p 
 0.05 vs
baseline) (Fig. 4D). Blocking G-protein activity did not, however,
prevent the potentiation of NMDA current by selective activation
of mGluR1 (10 M DHPG for 2 min in the presence of a
saturating concentration of the mGluR5 antagonist 10 M MPEP
for 10 min; 29  3%, n  5; p  0.01 vs baseline and p 
 0.05 vs
GDPS plus DHPG alone) (Fig. 4E). Thus the potentiation of
NMDA current by mGluR5, but not by mGluR1, absolutely
requires G-protein activation. The potentiation of NMDA cur-
rent induced by selective mGluR1 activation after G-protein
blockade was significantly greater than that induced by mGluR1
activation in control [18  4%, n  5 in presence of GTP (Fig. 3)
compared with 29  3%, n  5 in presence of GDPS; p  0.05
(Fig. 4)], suggesting that a G-protein-dependent process also may
antagonize mGluR-mediated potentiation of NMDA receptor
function (see Discussion).
Role of the PLC 3 DAG 3 PKC pathway in
mGluR-mediated potentiation of NMDA current
Having established that mGluR1 activation can potentiate NMDA
current via a G-protein-independent pathway, we addressed the
mechanism underlying G-protein-dependent potentiation via
mGluR5. Previous work in CA1 pyramidal cells has demonstrated
that the G-protein-dependent activation of a pathway involving the
sequential activation of PLC 3 DAG 3 PKC 3 Pyk2/CAK 3
Src induces tyrosine phosphorylation of NMDA receptors, result-
ing in their functional potentiation (Lu et al., 1999; Huang et al.,
2001). To obtain evidence for the activation of a similar pathway in
CA3 cells, we examined the effects of specifically blocking PKC, but
without blocking G-proteins. To facilitate the interpretation of our
results involving the PLC 3 DAG 3 PKC pathway, we tried to
minimize the contribution from the PLC3 IP33 Ca
2 pathway
by performing all of the subsequent experiments with BAPTA (10
mM) in the recording pipette solution (Adler et al., 1991). Intracel-
lular BAPTA resulted in significantly greater potentiation of
NMDA current in response to DHPG (10 M for 2 min) than with
EGTA as the intracellular Ca2 buffer (73 13%, n 6; p 0.05
vs EGTA solution) (Fig. 5A). Furthermore, the greater potentia-
tion with intracellular BAPTA was more apparent with the acti-
vation of mGluR1 than mGluR5 [10 M MPEP plus 10 M DHPG
potentiated by 41  13%, n  5 with BAPTA vs 18  4%, n  5
with EGTA; p  0.05; (data not shown); CHPG potentiated by
39  10%, n  7 with BAPTA vs 20  5%, n  8 with EGTA;
p 
 0.05 (Fig. 5A)].
The addition of the PKC inhibitor GF109203X (2 M for 20
min) to the bath prevented NMDA current potentiation in re-
sponse to selective mGluR5 activation (7  6%, n  6; p 
 0.05
vs baseline for CHPG 500 M; 10  8%, n  4; p 
 0.05 vs
baseline for 10 M DHPG plus 50 M CPCCOEt) (Fig. 5B,C). In
contrast, potentiation of NMDA current induced by the selective
activation of mGluR1 (10 M DHPG for 2 min plus 10 M MPEP
Figure 5. Blocking PKC activation prevents NMDA current potentiation
by mGluR5 but not by mGluR1. For all experiments with the PKC
inhibitor, GDPS was not present and BAPTA (10 mM) was used in the
pipette solution to minimize the Ca 2-dependent inhibition of NMDA
current. A, Left, Average time course of NMDA current potentiation
induced by DHPG (10 M for 2 min) either with EGTA (open circles; 10
mM; n 23) or with BAPTA ( filled circles; 10 mM; n 6) in the recording
pipette. A, Right, Data using the same protocol but with the mGluR5-
specific agonist CHPG (500 M for 2 min) either with EGTA (10 mM; n
8) or with BAPTA (10 mM; n  7) in the recording pipette. B, Inhibition
of PKC with the specific inhibitor GF109203X (2 M for 20 min) prevents
NMDA current potentiation in response to the mGluR5-specific agonist
CHPG (500 M for 2 min; n 6). Representative traces from one cell are
shown on the right. C, Similarly, inhibition of PKC prevents NMDA
current potentiation in response to mGluR5 activation by the application
of DHPG (10 M for 2 min; n  4) in the presence of a saturating
concentration of the mGluR1 antagonist CPCCOEt (50 M for 10 min).
Representative traces from one cell are shown on the right. D, In contrast,
the selective activation of mGluR1 by the application of DHPG (10 M
for 2 min) in the presence of a saturating concentration of the mGluR5
antagonist MPEP (10 M for 10 min) still potentiates NMDA current
under conditions in which PKC is blocked (n  5). Representative traces
from one cell are shown on the right. E, Average time course of NMDA
current potentiation induced by DHPG (10 M for 2 min; n  5) in the
presence of the PKC inhibitor. Representative traces from one cell are
shown on the right. F, Pooled data showing that, after the inhibition of
PKC, the selective activation of mGluR5 (CHPG, n  6; or LY367385
4
plus DHPG, n  4) does not potentiate NMDA current, whereas the
selective activation of mGluR1 (MPEP plus DHPG, n  5) induces a
potentiation comparable with that seen with the coactivation of mGluR1
plus mGluR5. Note that NMDA current potentiation induced by the
coactivation of mGluR1 plus mGluR5 after PKC inhibition is reduced but
still significant (n  5); *p  0.05.
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for 10 min) was not blocked after PKC inhibition with
GF109203X (33  6%, n  5; p  0.05 vs baseline) (Fig. 5D). We
observed that, after the selective activation of mGluR1 (DHPG
plus MPEP) in presence of BAPTA, the maximal degree of
potentiation with or without GF109203X was not significantly
different ( p 
 0.05).
Similarly, the potentiation of NMDA current with the activa-
tion of mGluR1 plus mGluR5 with DHPG (10 M for 2 min)
persisted in the presence of GF109203X (10 M for 2 min; 30 
7%, n  5; p  0.05 vs baseline) (Fig. 5E). Control experiments
showed that GF109203X completely blocked the potentiation of
NMDA currents induced by the bath application of PMA (250 nM
for 10 min), a PKC activator (28 3%, n 5, p 0.05 vs baseline
for PMA alone; 5 3%, n 4, p
 0.05 vs baseline for PMA plus
GF109203X; data not shown).
DISCUSSION
Our results show that in CA3 pyramidal cells the activation of
either postsynaptic mGluR1 or mGluR5 leads to potentiation of
NMDA receptor current via a Src-dependent mechanism. The
mGluR5-dependent potentiation of NMDA current is mediated
exclusively via G-protein- and PKC-dependent activation of Src,
whereas mGluR1-dependent potentiation can occur via
G-protein- and PKC-independent activation of Src. The upregu-
lation of NMDA responses by Src is well established, involving
the phosphorylation of receptor tyrosine residues, which in-
creases channel open probability (Salter, 1998; Ali and Salter,
2001). This mode of NMDA receptor enhancement can be trig-
gered by muscarinic or lysophosphatidic acid receptors (G-
protein-coupled receptors) or by receptors for leptin, EphB, or
BDNF (Levine et al., 1998; Lu et al., 1999; Shanley et al., 2001;
Takasu et al., 2002). Because mGluRs also have been shown to
activate Src (Fiore et al., 1993; Siciliano et al., 1994; Heuss et al.,
1999; Boxall, 2000; Peavy et al., 2001), the potentiation of NMDA
responses via this mechanism was not unexpected.
We have found that either mGluR1 or mGluR5 can mediate
NMDA current enhancement in CA3 pyramidal cells. In contrast,
studies in various other brain areas have identified mGluR5 as
uniquely responsible for NMDA receptor potentiation (Doherty
et al., 1997, 2000; Jia et al., 1998; Awad et al., 2000; Mannaioni et
al., 2001; Pisani et al., 2001). We interpret these findings as a
reflection of low mGluR1 expression, the presence of alternative
splice variants of mGluRs, or of a low incidence of colocalization
of mGluR1 and NMDA receptors in these other cell types. In
CA3 pyramidal cells immunohistochemical studies have revealed
postsynaptic localization of both mGluR1 and mGluR5 (Shige-
moto et al., 1997), and in Xenopus oocytes coexpressing mGluR1
and NMDA receptors metabotropic agonists do potentiate
NMDA responses (Lan et al., 2001; Skeberdis et al., 2001). A
recent study now has revealed mGluR1-mediated potentiation of
NMDA current in cortical neurons (Heidinger et al., 2002).
Our results suggest that synaptic NMDA currents are potenti-
ated by activation of group I mGluRs. As shown previously,
however, experiments to test this hypothesis are confounded by
the strong presynaptic depression of neurotransmitter release that
follows the activation of group I mGluRs (Gereau and Conn,
1995; Manzoni and Bockaert, 1995; Rodriguez-Moreno et al.,
1998; Fitzjohn et al., 2001; Mannaioni et al., 2001; Watabe et al.,
2002).
Signal transduction pathways
Earlier investigations into the transduction mechanisms underly-
ing mGluR-mediated upregulation of NMDA receptor function
have focused primarily on the possible involvement of the PLC/
PKC pathway. Approximately one-half of these studies concluded
that PKC activation is required for potentiation (Aniksztejn et
al., 1991; Kelso et al., 1992; Pisani et al., 1997; Ugolini et al., 1997;
Skeberdis et al., 2001), whereas others found no indication for
PKC involvement (Harvey and Collingridge, 1993; Kinney and
Slater, 1993; Rahman and Neuman, 1996; Holohean et al., 1999).
Our data provide a reasonable resolution for this discrepancy by
showing that both a PLC/PKC-dependent pathway as well as a
G-protein- and PKC-independent pathway can lead to Src-
mediated potentiation of NMDA current. Our results are consis-
tent with those from a recent study suggesting that mGluR5
signals via PKC to enhance NMDA-mediated responses (Jia et
al., 1998). A detailed characterization of this transduction path-
way in CA1 pyramidal cells has provided the following activation
sequence: G-protein3 PLC3 DAG3 PKC3 Pyk2/CAK3
Src 3 NMDA receptors (Lu et al., 1999; Huang et al., 2001).
Signal transduction via mGluR1 appears to be more complex.
We have shown previously in CA3 pyramidal cells that the same
population of synaptic mGluR1s, activated by the stimulation of
mossy fibers, signals via divergent pathways, one G-protein-
dependent and the other G-protein-independent (Heuss et al.,
1999). Although both pathways could be involved in the potenti-
ation of NMDA current by mGluR1, our data show that the
G-protein-independent mechanism predominates. Thus both
G-protein inhibition as well as PKC blockade (see also Heidinger
et al., 2002) did not prevent mGluR1-mediated potentiation.
The mechanism underlying the G-protein-independent activa-
tion of Src by mGluR1 is not known. In other systems G-protein-
independent signaling by metabotropic receptors can initiate the
binding of the adapter protein arrestin to the activated receptor,
resulting in the recruitment of Src (Hall et al., 1999). Arrestin has
been shown to bind to mGluR1a (Dale et al., 2001; Mundell et al.,
2001), but whether this association leads to Src activation remains
to be determined.
Modulation by Ca2
An unexpected observation in our study was that selective acti-
vation of mGluR1 resulted in significantly greater potentiation of
NMDA current after G-protein blockade than under control
conditions. Thus the activation of mGluRs appears to induce a
concomitant G-protein-dependent inhibition of NMDA current.
Both mGluR1 and mGluR5 mediate a G-protein-dependent re-
lease of intracellular calcium stores (Valenti et al., 2002). More-
over, NMDA receptor function is inhibited by a rise in intracel-
lular calcium (Mayer and Westbrook, 1985; Legendre et al., 1993;
Lieberman and Mody, 1994; Rosenmund et al., 1995). Hence it is
likely that the G-protein-dependent release of intracellular cal-
cium via mGluR activation will depress NMDA responses. Our
experimental protocol leads to an increase in intracellular Ca2
concentration via two mechanisms: (1) Ca2 influx through the
repetitively activated NMDA receptor channels and (2) Ca2
release from IP3-sensitive stores in response to G-protein-
dependent activation of PLC via mGluR stimulation. Further
evidence for our hypothesis is provided by the observation that
increasing the DHPG concentration to 50 M (3 min) in the
presence of 3 mM extracellular calcium with low intracellular
calcium buffering suppresses the potentiation (data not shown),
whereas accelerating intracellular Ca2 buffering by including
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BAPTA in the recording pipette substantially enhances the po-
tentiation of NMDA current and delays recovery of mGluR-
induced potentiation (Fig. 5A). Small differences in experimental
conditions affecting Ca2 homeostasis therefore may account for
the conflicting observations with respect to mGluR-mediated
effects on NMDA receptor function. Indeed, studies in which
relatively high levels of intracellular Ca2 would be expected,
either because of low Ca2 buffering or because of increased IP3
production induced by high mGluR agonist concentrations, re-
port mGluR-mediated reduction of NMDA current (Wang et al.,
1998; Zhong et al., 2000; Snyder et al., 2001). Similarly, in our
preparation high concentrations of DHPG (100 M; our unpub-
lished data) depressed NMDA current. However, an increase in
intracellular Ca2 also will enhance PKC activity (Nishizuka,
1988), which would potentiate NMDA responses via the Src
pathway. The net result of Ca2 on NMDA responses is thus
difficult to predict and is likely to depend on the extent and
compartmental localization of the intracellular Ca2 rise. In
addition to a Ca2-dependent reduction in NMDA current, it
should be pointed out that direct membrane-delimited inhibition
via G-proteins also may lead to NMDA current inhibition (Yu et
al., 1997).
Conclusion
Why should a neuron possess two parallel pathways to modulate
NMDA receptor function, one G-protein-dependent and one
G-protein-independent? G-protein function is controlled
through a complex interplay of regulatory molecules, permitting
both enhanced transduction as well as functional uncoupling of
G-proteins from cognate receptors (Alagarsamy et al., 2001). A
receptor system, which includes the added option of G-protein-
independent signaling, will provide a cell with greater flexibility
in responding to stimuli under a wide range of physiological and
pathophysiological conditions. Not only could certain responses
be maintained when G-protein-dependent pathways have been
shut off, but more focused activation of specific proteins would be
ensured. For example, in the case of mGluRs selective G-protein-
independent signaling would allow for the activation of Src with-
out the concomitant triggering of transduction cascades associ-
ated with PLC, PKC, or IP3.
Our finding that the coactivation of mGluR1 and mGluR5
induced larger responses than the activation of either subtype
alone suggests that the two receptor subtypes target different
populations of NMDA receptors (Salter, 2001). Thus mGluR1
receptors, which in CA3 cells can be activated synaptically (Heuss
et al., 1999), may modulate synaptic NMDA receptors, whereas
mGluR5 receptors in these cells might be activated primarily by
glutamate spillover and preferentially target extrasynaptic
NMDA receptors.
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